21:01:13 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Magle Chemoswed är verksamma inom läkemedelsbranschen. Bolaget är specialiserade inom utveckling av analytiska program. Produktportföljen är bred och inkluderar exempelvis program för intern uppföljning, process- samt systemhantering. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster inom arbetsområdet. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Magle Chemoswed har sitt huvudkontor i Malmö.

Kalender

2023-04-26 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-11-09 Kvartalsrapport 2022-Q3
2022-08-17 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning MAGLE 0.00 SEK
2022-05-17 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-25 Bokslutskommuniké 2021
2021-12-14 Extra Bolagsstämma 2021
2021-11-16 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-14 Kvartalsrapport 2021-Q1
2021-05-03 Ordinarie utdelning MAGLE 0.00 SEK
2021-04-18 Årsstämma 2021
2021-02-25 Bokslutskommuniké 2020
2020-11-27 Extra Bolagsstämma 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-07-14 Kvartalsrapport 2020-Q2

Prenumeration

2021-02-12 13:50:00

Magle Chemoswed announced today that it will participate in a development project funded by the European Union’s Horizon 2020 research and innovation program.

Project Carrier4TSC was selected as a proposal of high scientific importance and filling a market need and was evaluated by the Eurostar jury. The winning consortium is comprised of three partners with complementary competences and a common goal to bring a novel microcarrier to expand the yields of functional mesenchymal stem cells: denovoMATRIX GmbH and Technische Hochschule Mittelhessen are the other consortium partners.
 
“We are excited to have received funding from the European initiative and to move our technology platform to new areas of application that will make a real-world difference”, said Justin Pierce, CEO of Magle Chemoswed. “I am especially proud to join forces with denovoMATRIX and Technische Hochschule Mittelhessen. The combined knowledge and expertise in our consortium are a strong formula for success and future commercialisation of our developments”, added Justin Pierce.
 
The project is expected to start in May 2021 and is funded for three years. The purpose of the EU Project Carrier4TSC is to explore the development of a novel dissolvable microcarrier that enables the adhesion and growth of mesenchymal stem cells (MSC) in a bioreactor process, and an efficient cell harvest while preserving the therapeutic potential of MSC. The consortium will take advantage of denovoMATRIX and Magle Chemoswed’s background IP-portfolios and broad market outreach as wells as Magle Chemoswed’s experience with the production and technology platform with world leading knowledge in biomaterial modification by denovoMATRIX and bioprocess development of stem cells provided by Technische Hochschule Mittelhessen.